Related Experiment Video
Updated: Feb 10, 2026

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
Updates to the Management of Kidney Cancer
1Presented by Eric Jonasch, MD, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
Insights
The 2018 NCCN Guidelines for Kidney Cancer now include adjuvant sunitinib for stage II/III clear cell renal cell carcinoma (RCC). New frontline treatments, ipilimumab/nivolumab and cabozantinib, are also recommended for advanced RCC.
Area of Science:
- Oncology
- Nephrology
- Clinical Guidelines
Background:
- The National Comprehensive Cancer Network (NCCN) guidelines provide evidence-based recommendations for cancer care.
- Updates to these guidelines are crucial for reflecting advancements in treatment and patient management for renal cell carcinoma (RCC).
Purpose of the Study:
- To summarize key updates to the 2018 NCCN Guidelines for Kidney Cancer.
- To highlight newly endorsed therapies for specific stages and risk groups of renal cell carcinoma.
Main Methods:
- Review of the 2018 NCCN Guidelines for Kidney Cancer.
- Inclusion of new therapeutic options based on clinical evidence and expert panel consensus.
Main Results:
- Adjuvant sunitinib is recommended as the first adjuvant therapy for stage II and III clear cell histology renal cell carcinoma (RCC) (category 2B).
- Ipilimumab plus nivolumab is now included as a frontline treatment option for patients with intermediate and poor-risk advanced RCC.
- Cabozantinib has been added as a first-line treatment option for patients with advanced RCC who are classified as poor- or intermediate-risk.
Conclusions:
- The 2018 NCCN Guidelines for Kidney Cancer incorporate significant updates in adjuvant and frontline therapies.
- These updates provide clinicians with new evidence-based options for managing patients with renal cell carcinoma, particularly those with clear cell histology and advanced disease.
Related Concept Videos
Kidney Transplant III: Nursing Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease IV: Nursing Management
Kidney Structure
Tonsillitis II: Management
Kidney Transplant I: Introduction

